As Chinese biotech companies have faced a cash crunch at home, it has become necessary for them to look abroad for partnering opportunities to advance their assets through the clinic. This trend has led Johnson & Johnson to take an interest in linking arms with firms in China, albeit mindful of the current geopolitical climate, said Nauman Shah, global head of business development at Johnson & Johnson Innovation, at a 10 February fireside chat at the BIO CEO & Investor Conference.
Shah was not the only exec to raise the issue of how financing issues in China have spurred an increase in partnering.
Key Takeaways
- With Chinese biotech firms having difficulty coming by investment money, J&J is open to pursuing innovative treatments developed there, J&J Innovation’s business development head Nauman Shah said.
- The exec added that the situation is not likely to change in the immediate future, with firms in China wanting – and needing – to partner
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
